Compare GPRE & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | DRUG |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 744.9M |
| IPO Year | 2004 | 2020 |
| Metric | GPRE | DRUG |
|---|---|---|
| Price | $17.06 | $71.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.57 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 1.3M | 244.9K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | $40.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $31.80 |
| 52 Week High | $19.65 | $123.75 |
| Indicator | GPRE | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 48.39 |
| Support Level | $14.01 | $66.22 |
| Resistance Level | $17.94 | $71.91 |
| Average True Range (ATR) | 0.96 | 4.96 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 40.46 | 50.51 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.